schizophrenia and tobacco use More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology
Pay in 4 interest-free payments of $7.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
![schizophrenia and tobacco use More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology](https://cdn.neiglobal.com/content/tmip/2024/08-30_tmip_1600x1054.png)
![schizophrenia and tobacco use More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology](https://scitechdaily.com/images/Painting-Young-Man-Smoking-Schizophrenia-Mental-Health.jpg)
![schizophrenia and tobacco use More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41537-024-00449-1/MediaObjects/41537_2024_449_Fig1_HTML.png)
![schizophrenia and tobacco use More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology](https://ars.els-cdn.com/content/image/3-s2.0-B9780128025741000144-f14-01-9780128025741.jpg)























